loading...| Preferred Name |
Obinutuzumab |
|
| Synonyms |
|
|
| Definitions |
A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C70741 |
|
| Accepted_Therapeutic_Use_For |
follicular lymphoma (FL); chronic lymphocytic leukemia |
|
| CAS_Registry |
949142-50-1 |
|
| code |
C70741 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells. |
|
| Display_Name |
Obinutuzumab |
|
| FDA_UNII_Code |
O43472U9X8 |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Obinutuzumab |
|
| Legacy Concept Name |
Anti-CD20_Monoclonal_Antibody_R7159 |
|
| Maps_To |
Obinutuzumab |
|
| NCI_Drug_Dictionary_ID |
570643 |
|
| PDQ_Closed_Trial_Search_ID |
570643 |
|
| PDQ_Open_Trial_Search_ID |
570643 |
|
| Preferred_Name |
Obinutuzumab |
|
| prefixIRI |
NCIT:C70741 |
|
| prefLabel |
Obinutuzumab |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance Immunologic Factor |
|
| UMLS_CUI |
C2742503 |
|
| subClassOf |